» Articles » PMID: 15781624

Loss of the Inactive X Chromosome and Replication of the Active X in BRCA1-defective and Wild-type Breast Cancer Cells

Overview
Journal Cancer Res
Specialty Oncology
Date 2005 Mar 23
PMID 15781624
Citations 46
Authors
Affiliations
Soon will be listed here.
Abstract

In females, X chromosome inactivation (XCI) begins with the expression of the XIST gene from the X chromosome destined to be inactivated (Xi) and the coating of XIST RNA in cis. It has recently been reported that this process is supported by the product of the BRCA1 tumor suppressor gene and that BRCA1-/- cancers show Xi chromatin structure defects, thus suggesting a role of XCI perturbation in BRCA1-mediated tumorigenesis. Using a combined genetic and epigenetic approach, we verified the occurrence of XCI in BRCA1-/- and BRCA1wt breast cancer cell lines. It was ascertained that the Xi was lost in all cancer cell lines, irrespective of the BRCA1 status and that more than one active X (Xa) was present. In addition, no epigenetic silencing of genes normally subjected to XCI was observed. We also evaluated XIST expression and found that XIST may be occasionally transcribed also from Xa. Moreover, in one of the BRCA1wt cell line the restoring of XIST expression using a histone deacetylase inhibitor, did not lead to XCI. To verify these findings in primary tumors, chromosome X behavior was investigated in a few BRCA1-associated and BRCA1-not associated primary noncultured breast carcinomas and the results mirrored those obtained in cancer cell lines. Our findings indicate that the lack of XCI may be a frequent phenomenon in breast tumorigenesis, which occurs independently of BRCA1 status and XIST expression and is due to the loss of Xi and replication of Xa and not to the reactivation of the native Xi.

Citing Articles

Oncogenes and tumor suppressor genes: functions and roles in cancers.

Dakal T, Dhabhai B, Pant A, Moar K, Chaudhary K, Yadav V MedComm (2020). 2024; 5(6):e582.

PMID: 38827026 PMC: 11141506. DOI: 10.1002/mco2.582.


XIST and MUC1-C form an auto-regulatory pathway in driving cancer progression.

Wang K, Bhattacharya A, Haratake N, Daimon T, Nakashoji A, Ozawa H Cell Death Dis. 2024; 15(5):330.

PMID: 38740827 PMC: 11091074. DOI: 10.1038/s41419-024-06684-9.


Sex and gender perspectives in colorectal cancer.

Baraibar I, Ros J, Saoudi N, Salva F, Garcia A, Castells M ESMO Open. 2023; 8(2):101204.

PMID: 37018873 PMC: 10163160. DOI: 10.1016/j.esmoop.2023.101204.


LncRNA XIST regulates breast cancer stem cells by activating proinflammatory IL-6/STAT3 signaling.

Ma Y, Zhu Y, Shang L, Qiu Y, Shen N, Wang J Oncogene. 2023; 42(18):1419-1437.

PMID: 36922677 PMC: 10154203. DOI: 10.1038/s41388-023-02652-3.


Distinct dosage compensations of ploidy-sensitive and -insensitive X chromosome genes during development and in diseases.

Guo M, Fang Z, Chen B, Songyang Z, Xiong Y iScience. 2023; 26(2):105997.

PMID: 36798435 PMC: 9926305. DOI: 10.1016/j.isci.2023.105997.